Lambert Eaton Myasthenic Syndrome.

Area of Science:

• Neurology
• Neuroscience
• Immunology

Background:

• Lambert Eaton Myasthenic Syndrome (LEMS) is a rare pre-synaptic neuromuscular junction disorder.
• Characterized by proximal muscle weakness, reduced reflexes, and autonomic dysfunction.
• Often associated with small cell lung cancer (SCLC).

Purpose of the Study:

• To summarize the clinical, electrophysiological, immunological, and pathological features of LEMS.
• To discuss the pathophysiology of reduced acetylcholine release in LEMS.
• To outline current treatment strategies and prognostic factors for LEMS.

Main Methods:

• Review of clinical presentations and diagnostic criteria for LEMS.
• Analysis of typical electrophysiological findings in LEMS.
• Discussion of immunological markers, particularly anti-voltage-gated calcium channel antibodies.
• Examination of the association between LEMS and malignancy, especially SCLC.

Main Results:

• LEMS presents with leg-predominant proximal weakness, autonomic symptoms, and reduced reflexes.
• Electrophysiology shows small compound muscle action potentials with characteristic responses to repetitive nerve stimulation.
• Anti-voltage-gated calcium channel antibodies are found in most LEMS patients.
• Approximately 50% of LEMS cases are paraneoplastic, linked to SCLC.

Conclusions:

• LEMS results from reduced pre-synaptic acetylcholine release, leading to muscle weakness.
• Treatment involves symptomatic therapies (e.g., amifampridine), immunotherapy, and addressing underlying malignancy.
• Prognosis for non-paraneoplastic LEMS is generally good with normal life expectancy.
• Prognosis for paraneoplastic LEMS depends on the management of the associated SCLC.